A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

• ClinicalTrials.gov Identifier: NCT00954798
• Recruitment Status: Completed
• Last Update Posted: January 14, 2014
• Sponsor: Sanofi Pasteur, a Sanofi Company
• Information provided by (Responsible Party): Sanofi ( Sanofi Pasteur, a Sanofi Company )

Study Description

Brief Summary:

The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.

Primary objectives:

• To describe the immune response to study vaccine 21 days after each vaccination.
• To describe the antibody persistence 8 months after the first vaccine administration using hemagglutination inhibition (HAI) method in a randomized subset of adult subjects who received two injections.
• To describe the immune response against the A/H1N1 strain using HAI method 21 days after a vaccination with the 2010-2011 Northern Hemisphere (NH) seasonal trivalent influenza vaccine (TIV) administered 13 months after the first vaccination in a subset subjects who received the A/H1N1 influenza vaccine and in subjects naïve to the swine origin A/H1N1 strain.
• To describe the safety profiles of study vaccines in all participants.

Condition or disease	Intervention/treatment	Phase
Influenza; Swine-origin A/H1N1 Influenza	Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated)	Phase 2

Detailed Description:

All participants will receive two injections of their randomized vaccine on Day 0 and Day 21, respectively.

A subset of the participants will receive a third vaccine injection (2010-2011 Northern Hemisphere [NH] seasonal trivalent influenza vaccine [TIV]) approximately 13 months after the first vaccination; additionally, a subset of participants' naïve to the swine-origin A/H1N1 strain will also receive one vaccine injection of the 2010-2011 NH seasonal TIV.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 450 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly Subjects
• Study Start Date: August 2009
• Actual Primary Completion Date: December 2010
• Actual Study Completion Date: March 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: A/H1N1 Vaccine Group 1; All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.	Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated); 0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
Experimental: A/H1N1 Vaccine Group 2; All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.	Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated); 0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
Experimental: A/H1N1 Vaccine Group 3; Participants will receive A/H1N1 vaccine formulation 3	Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated); 0.5 mL, Intramuscular on Day 0 and Day 21

Outcome Measures

Primary Outcome Measures :

1. To provide information concerning the immunogenicity of Swine A/H1N1 influenza vaccine [ Time Frame: 21 days post-vaccination ]
2. To provide information concerning the safety in terms of solicited injection site and systemic reactions following vaccination with Swine A/H1N1 influenza vaccine [ Time Frame: 0 to7 days post-vaccination and entire study duration ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria :

• Aged 18 years or over on the day of inclusion
• Informed Consent Form has been signed and dated
• Able to attend all scheduled visits and to comply with all trial procedures
• For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination
• Entitled to national social security

At Visit 05, for antibody persistence assessment:

• Addendum 1 to Informed Consent Form has been signed and dated
• Having received two vaccinations with the vaccine formulation 1 or 2.

At Month 13, for trivalent influenza vaccine (TIV) administration in subjects who received the A/H1N1 influenza vaccine:

- Addendum 2 to Informed Consent Form has been signed and dated

Exclusion Criteria :

• Known pregnancy, or a positive urine pregnancy test
• Currently breastfeeding a child
• Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
• Planned participation in another clinical trial during the present trial period
• Receipt of any vaccine in the 4 weeks preceding the first trial vaccination
• Planned receipt of any vaccine prior to the Day 42 blood sample
• Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
• Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
• Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
• Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
• Employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
• Previous participation in a trial investigating a vaccine with the swine-origin A/H1N1 influenza strain
• Confirmed infection with the swine-origin A/H1N1 influenza strain (different from the seasonal strain) in 2009
• Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment
• Receipt of any allergy shots and/or seasonal allergy medication in the 7-day period prior to enrollment (vaccination), or scheduled to receive any allergy shots and/or seasonal allergy medication in the 7-day period after enrollment (vaccination)

At Month 8, for antibody persistence assessment:

- Subjects who received, in the context of a pandemic immunization program, another A/H1N1 pandemic influenza vaccine than the Investigational Medicinal Products.

Additional criteria for subset to receive only the TIV:

• History of pandemic A/H1N1 influenza vaccination
• History of clinically or laboratory confirmed pandemic A/H1N1 influenza infection
• Receipt of an adjuvanted influenza vaccine in a clinical trial within the previous 12 months
• Planned receipt of any vaccine during the present trial period.

Contacts and Locations

Locations

France

Angers, France, 49000

Chateau Gontier, France, 53200

Cherbourg, France, 50100

Equeurdreville, France, 50120

Laval, France, 53000

Tierce, France, 49125

Sponsors and Collaborators

Sanofi Pasteur, a Sanofi Company

Investigators

• Study Director: Medical Monitor; Sanofi Pasteur Inc.

More Information

Additional Information:

Related Info 

Related Info 

• Responsible Party: Sanofi Pasteur, a Sanofi Company
• ClinicalTrials.gov Identifier: NCT00954798
• Other Study ID Numbers: GPF07; UTN: U1111-1111-4918; 2009-013344-37 ( EudraCT Number )
• First Posted: August 7, 2009
• Last Update Posted: January 14, 2014
• Last Verified: January 2014

Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):

Influenza; Pandemic Flu; Swine-origin Influenza; Inactivated split-virion vaccine; Adjuvant; Adult

Additional relevant MeSH terms:

Influenza, Human; Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Vaccines; Immunologic Factors; Physiological Effects of Drugs